Hormone therapyFDA-approvedSecond-line
Nubeqa
Generic name: darolutamide
How it works
Blocks the action of testosterone on cancer cells, slowing growth.
Cancer types
Prostate Cancer— All patients
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with median overall survival of approximately 20 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Darolutamide and ADT Before Surgery for High-Risk Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Observing Darolutamide's Effectiveness in Non-metastatic Castration-resistant Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Study of Darolutamide and ADT for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Darolutamide with Hormonal Therapy for High-Risk Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Study of Darolutamide in Combination with Androgen Deprivation Therapy and Docetaxel for Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Safety Study of Darolutamide in Men with Metastatic Prostate Cancer | Prostate Cancer | preclinical | — | Source → |
| Men with Advanced Prostate Cancer to Receive Darolutamide and Hormone Therapy in Real-world Medical Practice | Prostate Cancer | phase-3 | — | Source → |
| Testing Darolutamide with Surgery for High-Risk Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Comparing Darolutamide with Androgen Deprivation Therapy in Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Studying Darolutamide Safety in Korean Men with Prostate Cancer | Prostate Cancer | preclinical | — | Source → |
| Testing Testosterone and Darolutamide for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Darolutamide's Benefit in Prostate Cancer Treatment | Prostate Cancer | phase-3 | In the Japanese subgroup, the probability that the darolutamide triplet provided greater utility was 0.601 when considering three criteria, and 0.975 when considering four criteria, including time to castration-resistant prostate cancer. | Source → |
| New Insights into Prostate Cancer Treatment Options | Prostate Cancer | meta-analysis | Darolutamide + docetaxel + ADT showed significant benefit over docetaxel + ADT, ADT and standard-nonsteroidal-antiandrogen + ADT in all analyses. | Source → |
| Darolutamide and Hormone Therapy for Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-3 | Treatment with enzalutamide + ADT significantly prolonged the primary endpoint of radiographic progression-free survival (HR [95% confidence interval, CI]: 0.54 [0.32-0.93], p = 0.03) compared with darolutamide + ADT. | Source → |
| Darolutamide Improves Prostate Cancer Treatment for Black Patients | Prostate Cancer | observational | Darolutamide + ADT resulted in an additional 1.04 (95% uncertainty interval 0.56-1.51) QALYs per treated patient relative to ADT, with the greatest gain observed among NH-Black patients (1.48 [0.48-2.71]). | Source → |
| New Combination Therapy Shows Promise for Prostate Cancer | Prostate Cancer | phase-3 | No significant differences in overall survival were found between the doublet regimen and the control group (hazard ratio: 0.81; 95% confidence interval: 0.59-1.12). | Source → |
| Darolutamide Efficacy in Japanese Prostate Cancer Patients | Prostate Cancer | phase-3 | — | Source → |
| Darolutamide Shows Promise in Treating Advanced Prostate Cancer | Prostate Cancer | phase-2 | The median time to PSA50 in the Darolutamide group was 1.5 months, significantly lower than that in the placebo group (3.0 months). | Source → |
| Darolutamide Improves Prostate Cancer Progression in Phase III Trial | Prostate Cancer | phase-3 | Darolutamide plus hormone therapy reduced the risk of radiological progression or death by 46% versus placebo plus hormone therapy. | Source → |
| Short-term Darolutamide with Radiation Therapy for Prostate Cancer | Prostate Cancer | phase-2 | Six months of darolutamide + EBRT compared with 6 months of ADT + EBRT may be efficient in terms of a biological response. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.